Skip to main content
Erschienen in: Die Urologie 3/2009

01.03.2009 | Leitthema

Botulinumtoxin bei nichtneurogenen Blasenfunktionsstörungen

verfasst von: U. Mehnert, Prof. Dr. B. Schurch

Erschienen in: Die Urologie | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die nichtneurogene überaktive Harnblase mit oder ohne Detrusorüberaktivität und/oder Inkontinenz ist ein belastendes Symptom für viele Menschen, das bis vor wenigen Jahren nur mit anticholinergen Medikamenten oder operativ behandelt werden konnte. Intradetrusorinjektionen mit Botulinumtoxin Typ A stellen eine minimal-invasive Alternative für Patienten dar, die auf Anticholinergika nicht ansprechen oder diese nicht vertragen. Dieser Übersichtsartikel fasst die relevanten Arbeiten der letzten 6 Jahre zu diesem Thema zusammen und gibt Auskunft über die Wirksamkeit, die Nebenwirkungen, die verwendeten Dosierungen und Injektionstechniken. Insgesamt zeigte sich eine gute initiale Wirksamkeit, die etwa ab dem 4. Tag nach Injektion beginnt und durchschnittlich bis zu 31 Wochen anhalten kann. Es ist allerdings je nach Dosis mit einer Erhöhung der Restharnmengen zu rechnen, die auch die Anwendung von intermittierendem Selbstkatheterismus notwendig machen können. Die Anwendung von Botulinumtoxin in der Harnblase ist noch immer keine offiziell zugelassene Therapie.
Literatur
1.
Zurück zum Zitat Wein AJ, Rackley RR (2006) Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 175: 5–10CrossRef Wein AJ, Rackley RR (2006) Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 175: 5–10CrossRef
2.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1315PubMedCrossRef Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1315PubMedCrossRef
3.
Zurück zum Zitat Klotz T, Bruggenjurgen B, Burkart M et al (2007) The economic costs of overactive bladder in Germany. Eur Urol 51: 1654–1663PubMedCrossRef Klotz T, Bruggenjurgen B, Burkart M et al (2007) The economic costs of overactive bladder in Germany. Eur Urol 51: 1654–1663PubMedCrossRef
4.
Zurück zum Zitat Irwin DE, Milsom I, Kopp Z et al (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53: 1029–1037PubMedCrossRef Irwin DE, Milsom I, Kopp Z et al (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53: 1029–1037PubMedCrossRef
5.
Zurück zum Zitat Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175: 191–195PubMedCrossRef Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175: 191–195PubMedCrossRef
6.
Zurück zum Zitat Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53: 275–287PubMedCrossRef Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53: 275–287PubMedCrossRef
7.
Zurück zum Zitat Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977–983PubMedCrossRef Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977–983PubMedCrossRef
8.
Zurück zum Zitat Khera M, Somogyi GT, Salas NA et al (2005) In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 66: 208–212PubMedCrossRef Khera M, Somogyi GT, Salas NA et al (2005) In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 66: 208–212PubMedCrossRef
9.
Zurück zum Zitat Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26: 531–536PubMedCrossRef Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26: 531–536PubMedCrossRef
10.
Zurück zum Zitat Ghei M, Maraj BH, Miller R et al (2005) Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174: 1873–1877PubMedCrossRef Ghei M, Maraj BH, Miller R et al (2005) Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174: 1873–1877PubMedCrossRef
11.
Zurück zum Zitat Hirst GR, Watkins AJ, Guerrero K et al (2007) Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 69: 69–73PubMedCrossRef Hirst GR, Watkins AJ, Guerrero K et al (2007) Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 69: 69–73PubMedCrossRef
12.
Zurück zum Zitat Kalsi V, Apostolidis A, Gonzales G et al (2008) Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 54: 181–187PubMedCrossRef Kalsi V, Apostolidis A, Gonzales G et al (2008) Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 54: 181–187PubMedCrossRef
13.
Zurück zum Zitat Kalsi V, Apostolidis A, Popat R et al (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49: 528–535PubMedCrossRef Kalsi V, Apostolidis A, Popat R et al (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49: 528–535PubMedCrossRef
14.
Zurück zum Zitat Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49: 519–527PubMedCrossRef Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49: 519–527PubMedCrossRef
15.
Zurück zum Zitat Kessler TM, Danuser H, Schumacher M et al (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24: 231–236PubMedCrossRef Kessler TM, Danuser H, Schumacher M et al (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24: 231–236PubMedCrossRef
16.
Zurück zum Zitat Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63: 868–872PubMedCrossRef Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63: 868–872PubMedCrossRef
17.
Zurück zum Zitat Kuo HC (2006) Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68: 993–998PubMedCrossRef Kuo HC (2006) Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68: 993–998PubMedCrossRef
18.
Zurück zum Zitat Popat R, Apostolidis A, Kalsi V et al (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174: 984–989PubMedCrossRef Popat R, Apostolidis A, Kalsi V et al (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174: 984–989PubMedCrossRef
19.
Zurück zum Zitat Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63: 1071–1075PubMedCrossRef Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63: 1071–1075PubMedCrossRef
20.
Zurück zum Zitat Smith CP, Nishiguchi J, O’Leary M et al (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65: 37–41PubMedCrossRef Smith CP, Nishiguchi J, O’Leary M et al (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65: 37–41PubMedCrossRef
21.
Zurück zum Zitat Dykstra D, Enriquez A, Valley M (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14: 424–426PubMedCrossRef Dykstra D, Enriquez A, Valley M (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14: 424–426PubMedCrossRef
22.
Zurück zum Zitat Brubaker L, Richter HE, Visco A et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180: 217–222PubMedCrossRef Brubaker L, Richter HE, Visco A et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180: 217–222PubMedCrossRef
23.
Zurück zum Zitat Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177: 2231–2236PubMedCrossRef Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177: 2231–2236PubMedCrossRef
24.
Zurück zum Zitat Flynn MK, Webster GD, Amundsen CL (2004) The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172: 2316–2320PubMedCrossRef Flynn MK, Webster GD, Amundsen CL (2004) The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172: 2316–2320PubMedCrossRef
25.
Zurück zum Zitat Jeffery S, Fynes M, Lee F et al (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100: 1302–1306PubMedCrossRef Jeffery S, Fynes M, Lee F et al (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100: 1302–1306PubMedCrossRef
26.
Zurück zum Zitat Karsenty G, Elzayat E, Delapparent T et al (2007) Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 177: 1011–1014PubMedCrossRef Karsenty G, Elzayat E, Delapparent T et al (2007) Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 177: 1011–1014PubMedCrossRef
27.
Zurück zum Zitat Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66: 94–98PubMedCrossRef Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66: 94–98PubMedCrossRef
28.
Zurück zum Zitat Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178: 1359–1363PubMedCrossRef Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178: 1359–1363PubMedCrossRef
29.
Zurück zum Zitat Rajkumar GN, Small DR, Mustafa AW et al (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96: 848–852PubMedCrossRef Rajkumar GN, Small DR, Mustafa AW et al (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96: 848–852PubMedCrossRef
30.
Zurück zum Zitat Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176: 177–185PubMedCrossRef Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176: 177–185PubMedCrossRef
31.
Zurück zum Zitat Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48: 984–990PubMedCrossRef Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48: 984–990PubMedCrossRef
32.
Zurück zum Zitat Werner M, Schmid DM, Schussler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192: 1735–1740PubMedCrossRef Werner M, Schmid DM, Schussler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192: 1735–1740PubMedCrossRef
33.
Zurück zum Zitat Karsenty G, Reitz A, Lindemann G et al (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68: 1193–1197PubMedCrossRef Karsenty G, Reitz A, Lindemann G et al (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68: 1193–1197PubMedCrossRef
34.
Zurück zum Zitat Reitz A, Denys P, Fermanian C et al (2007) Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52: 1729–1735PubMedCrossRef Reitz A, Denys P, Fermanian C et al (2007) Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52: 1729–1735PubMedCrossRef
35.
Zurück zum Zitat Gousse A, Cohen B, Rodriguez D et al (2007) Scheduled repeated Botox injections for idiopathic OAB: evaluating therapeutic time. J Urol 177: 39CrossRef Gousse A, Cohen B, Rodriguez D et al (2007) Scheduled repeated Botox injections for idiopathic OAB: evaluating therapeutic time. J Urol 177: 39CrossRef
36.
Zurück zum Zitat Cohen BL, Barboglio P, Rodriguez D et al (2008) Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn (Epub ahead of print) Cohen BL, Barboglio P, Rodriguez D et al (2008) Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn (Epub ahead of print)
37.
Zurück zum Zitat Lucioni A, Rapp DE, Gong EM et al (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can J Urol 13: 3291–3295PubMed Lucioni A, Rapp DE, Gong EM et al (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can J Urol 13: 3291–3295PubMed
38.
Zurück zum Zitat Karsenty G, Boy S, Reitz A et al (2005) Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence. A prospective randomized study to compare 30 vs. 10 injection sites. Neurourol Urodyn 24: 547 Karsenty G, Boy S, Reitz A et al (2005) Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence. A prospective randomized study to compare 30 vs. 10 injection sites. Neurourol Urodyn 24: 547
39.
Zurück zum Zitat Smith CP, Chancellor MB (2005) Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 19: 880–882PubMedCrossRef Smith CP, Chancellor MB (2005) Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 19: 880–882PubMedCrossRef
40.
Zurück zum Zitat Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 13(Suppl 1): 11–15PubMedCrossRef Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 13(Suppl 1): 11–15PubMedCrossRef
Metadaten
Titel
Botulinumtoxin bei nichtneurogenen Blasenfunktionsstörungen
verfasst von
U. Mehnert
Prof. Dr. B. Schurch
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 3/2009
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-008-1918-8

Weitere Artikel der Ausgabe 3/2009

Die Urologie 3/2009 Zur Ausgabe

Berufspolitik BDU

Berufspolitik BDU

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.